Outcomes of early-stage breast cancer patients treated with sequential anthracyclines–taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial
Outcomes of early-stage breast cancer patients treated with sequential anthracyclines–taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial
复制标题
序贯蒽环类-紫杉烷类药物治疗的早期乳腺癌患者的结果与相对剂量强度的关系：随机对照试验的二次分析
DOI：
--
复制
发表时间：
2018
影响因子：
3.4
通讯作者：
Omar Abdel
中科院分区：
文献类型：
--
作者：
Omar Abdel;Omar Abdel
目的探讨相对给药强度（RDI）对蒽环类紫杉烷辅助化疗乳腺癌患者预后的影响。方法：这是对BCIRG005研究比较组中接受阿霉素/环磷酰胺(AC) -多西他赛辅助治疗方案的患者结果的二次分析。通过Kaplan-Meier分析，根据RDI评估总生存率。通过Cox回归分析对影响总生存期的参数进行单因素和多因素分析。结果根据RDI对AC-docetaxel方案的总生存率进行kaplan - meier分析（< 90 vs≥90%），结果显示RDI < 90%与总生存率差相关（P = 0.006）。单因素Cox回归分析显示，年龄、T分期、淋巴结比例、激素受体状态、ac -多西他赛方案的疾病分级和RDI对总生存率有显著影响（P < 0.05）。当将这些因素纳入多因素分析时，以下因素与较差的总生存率相关：年龄小于40岁（P < 0.0001）、T分期较大（P < 0.0001）、淋巴结比例较大（P < 0.0001）、激素受体状态阴性（P = 0.001）、高分级（P < 0.0001）和RDI≤90% （P = 0.015）。RDI与激素受体状态的正式交互检验P值不显著（P = 0.794）。结论整个蒽环类药物-紫杉烷方案的RDI越低，患者生存越差。应尽一切努力避免接受蒽环类-紫杉烷辅助化疗的早期乳腺癌患者不必要的剂量减少和/或中断。
PurposeTo assess the impact of relative dosing intensity (RDI) on the outcomes of breast cancer patients referred for adjuvant anthracycline–taxane chemotherapy.MethodsThis is a secondary analysis of the outcomes of patients in the comparator arm of the BCIRG005 study who received adjuvant adriamycin/cyclophosphamide (AC)–docetaxel regimen. Overall survival was assessed according to RDI through Kaplan–Meier analysis. Univariate and multivariate analyses of parameters affecting overall survival were then conducted through Cox regression analysis.ResultsKaplan–Meier analysis of overall survival according to RDI for the AC–docetaxel regimen (< 90 vs. ≥ 90%) was conducted and it showed that RDI < 90% is associated with worse overall survival (P = 0.006). In univariate Cox regression analysis, the following parameters significantly affected overall survival (P < 0.05): age, T stage, lymph node ratio, hormone receptor status, and grade of the disease and RDI for AC–docetaxel regimen. When these factors were included in multivariate analysis, the following factors were associated with worse overall survival: age less than 40 years (P < 0.0001), greater T stage (P < 0.0001), greater lymph node ratio (P < 0.0001), negative hormone receptor status (P = 0.001), high grade (P < 0.0001) and RDI ≤ 90% (P = 0.015). Formal interaction testing between RDI and hormone receptor status has a non-significant P value (P = 0.794).ConclusionLower RDI for the whole anthracycline–taxane protocol is associated with worse patient survival. Every effort should be exercised to avoid unnecessary dose reductions and/or interruptions among early breast cancer patients receiving adjuvant anthracycline–taxane chemotherapy.
影响因子：
158.5
作者：
Sparano, Joseph A.;Wang, Molin;Davidson, Nancy E.
通讯作者：
Davidson, Nancy E.